Anúncio
Anúncio
TCRX
TScan Therapeutics, Inc. Common Stock
1.21
USDPatrocinado
+0.04
+2.97%
09 de jan., 15:59 UTC -5
Encerrado
Pré-Mercado
1.22
+0.01
+0.41%
Relatórios de Lucros TCRX
Rácio de surpresa positiva
TCRX separação 12 de 18 últimas estimativas.
67%
Próximo Relatório
Data do Próximo Relatório
04 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.09M
/-$0.24
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-16.81%
/-14.29%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+214.13%
/-20.00%
TScan Therapeutics, Inc. Common Stock earnings per share and revenue
On 12 de nov. de 2025, TCRX reported earnings of -0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.30 USD, resulting in a 7.04% surprise. Revenue reached 2.51 milhão, compared to an expected 2.02 milhão, with a 24.33% difference. The market reacted with a -2.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analistas forecast an EPS of -0.24 USD, with revenue projected to reach 2.09 milhão USD, implying an diminuir of -14.29% EPS, and diminuir of -16.81% in Revenue from the last quarter.
FAQ
What were TScan Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, TScan Therapeutics, Inc. Common Stock reported EPS of -$0.28, beating estimates by 7.04%, and revenue of $2.51M, 24.33% above expectations.
How did the market react to TScan Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -2.46%, changed from $1.22 before the earnings release to $1.19 the day after.
When is TScan Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 04 de mar. de 2026.
What are the forecasts for TScan Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analistas, TScan Therapeutics, Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $2.09M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio